We can't find the internet
Attempting to reconnect
17448.1 PFLS-LS
17448.1 PFLS-LS
Résumé
Antibody-Mediated Beta-Cell Protection for the Treatment of Type-2 Diabetes
Textes supplémentaires
Abstract
The project is aimed at elucidating the mechanism of action of a newly developed disease-modifying immunotherapy for type-2 diabetes, along with the identification of biomarkers for patient selection and monitoring of the clinical response. The resulting data package will allow for the progression of this experimental therapy towards clinical development and partnering with a major biopharmaceutical company.
Participants
Michael Salzmann
Wirtschaftspartner
michael.salzmann@neurimmune.com
Neurimmune Holding AG Michael Salzmann Wagistrasse 13 8952 Schlieren ZH CH
Roger Nitsch
Kontaktperson
nitsch@bli.uzh.ch
Universität Zürich Roger Nitsch Wagistrasse 14 8952 Schlieren ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2014-12-31
- Date de fin
- 2017-02-28
- Coûts totaux approuvés
- CHF 998535.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T490 Biotechnology 100.0%